Mannatech Swings to Q3 Profit Amidst Declining Sales, Cash Drain

TL;DR

**MTEX's Q3 profit is a mirage; declining sales and a cash burn mean this stock is a short-term gamble at best.**

AI Summary

Mannatech Inc. (MTEX) reported a net income of $1.924 million for the three months ended September 30, 2025, a significant turnaround from a net loss of $0.328 million in the same period of 2024. However, for the nine months ended September 30, 2025, the company posted a net loss of $3.918 million, compared to a net income of $0.228 million in the prior year. Net sales decreased to $29.161 million for the three-month period in 2025 from $31.725 million in 2024, and for the nine-month period, net sales fell to $81.403 million from $88.858 million. Operating expenses saw a reduction, with commissions and incentives decreasing by $1.701 million and selling and administrative expenses by $0.768 million for the three months ended September 30, 2025, compared to the prior year. Cash and cash equivalents declined from $11.396 million at December 31, 2024, to $7.141 million at September 30, 2025, primarily due to $2.674 million net cash used in operating activities and $1.179 million in investing activities during the nine-month period. The company's total assets decreased from $36.056 million to $33.920 million over the same period, while total liabilities saw a slight reduction from $27.442 million to $26.970 million.

Why It Matters

Mannatech's ability to generate a quarterly profit despite declining sales suggests cost-cutting measures are taking hold, which could be a positive signal for investors. However, the year-to-date net loss and significant cash burn from operations raise concerns about long-term sustainability and growth prospects in a competitive nutritional supplements market. Employees might face continued pressure on compensation and incentives given the overall sales decline, while customers could see shifts in product offerings or marketing strategies. The broader market will watch if MTEX can stabilize its top-line revenue and reverse the negative cash flow trend, especially as it competes with larger, more diversified health and wellness companies.

Risk Assessment

Risk Level: high — Mannatech reported a net loss of $3.918 million for the nine months ended September 30, 2025, a significant deterioration from a $0.228 million net income in the prior year. Furthermore, the company experienced a net cash outflow of $2.674 million from operating activities during the nine-month period, indicating that its core business is not generating sufficient cash to sustain operations.

Analyst Insight

Investors should exercise extreme caution and consider avoiding MTEX given the persistent decline in net sales and the substantial net cash used in operating activities. Await clear evidence of sustained revenue growth and positive operating cash flow before considering any investment.

Financial Highlights

revenue

$81.403M

total Assets

$33.920M

total Debt

$6.651M

net Income

($3.918M)

gross Margin

74.8%

cash Position

$7.141M

revenue Growth

-8.4%

Key Numbers

• $1.924M — Net Income (Q3 2025) (Significant turnaround from a $0.328M net loss in Q3 2024.)
• ($3.918M) — Net Loss (YTD Sept 2025) (Deterioration from a $0.228M net income in YTD Sept 2024.)
• $29.161M — Net Sales (Q3 2025) (Decreased from $31.725M in Q3 2024.)
• $81.403M — Net Sales (YTD Sept 2025) (Decreased from $88.858M in YTD Sept 2024.)
• $7.141M — Cash and Cash Equivalents (Sept 30, 2025) (Down from $11.396M at Dec 31, 2024.)
• ($2.674M) — Net Cash Used in Operating Activities (YTD Sept 2025) (Indicates core business is not generating cash.)
• $33.920M — Total Assets (Sept 30, 2025) (Decreased from $36.056M at Dec 31, 2024.)
• 1,900,930 — Common Shares Outstanding (Sept 30, 2025) (Slight increase from 1,884,814 at Dec 31, 2024.)

Key Players & Entities

• MANNATECH, INCORPORATED (company) — Registrant as Specified in its Charter
• MTEX (company) — Trading Symbol on Nasdaq
• Nasdaq Global Select Market (regulator) — Exchange where MTEX is listed
• Meitai Daily Necessity & Health Products Co., Ltd. (company) — Mannatech's subsidiary in China
• United States Securities and Exchange Commission (regulator) — Regulatory body for filing
• $1.924 million (dollar_amount) — Net income for Q3 2025
• $0.328 million (dollar_amount) — Net loss for Q3 2024
• $3.918 million (dollar_amount) — Net loss for nine months ended Sept 30, 2025
• $29.161 million (dollar_amount) — Net sales for Q3 2025
• $81.403 million (dollar_amount) — Net sales for nine months ended Sept 30, 2025

FAQ

Risk Factors

• Declining Sales and Profitability [high — financial]: Net sales decreased by 8.1% to $29.161 million in Q3 2025 and by 8.4% to $81.403 million year-to-date compared to the prior year periods. The company also experienced a significant net loss of $3.918 million year-to-date in 2025, a reversal from a net income of $0.228 million in 2024, indicating persistent challenges in generating sustainable profits.
• Deteriorating Cash Position [high — financial]: Cash and cash equivalents have fallen from $11.396 million at the end of 2024 to $7.141 million as of September 30, 2025. This decline is largely attributed to $2.674 million in net cash used in operating activities year-to-date, highlighting a core business that is not generating sufficient cash flow.
• Inventory Management Challenges [medium — operational]: Inventories have increased from $10.405 million at December 31, 2024, to $11.128 million at September 30, 2025. This build-up, coupled with declining sales, could indicate potential issues with inventory turnover and obsolescence, leading to increased carrying costs and potential write-downs.
• Reduced Operating Expenses Not Fully Offsetting Sales Decline [medium — financial]: While the company reduced operating expenses, including commissions and incentives by $1.701 million and selling and administrative expenses by $0.768 million in Q3 2025 compared to Q3 2024, these savings were insufficient to counter the revenue drop and the year-to-date net loss.
• Leverage from Operating Leases [low — financial]: Operating lease liabilities (including current portion) have increased from $2.754 million at December 31, 2024, to $4.447 million at September 30, 2025. This rise in lease obligations, alongside other liabilities, contributes to the company's overall financial structure.

Industry Context

Mannatech operates in the direct selling and nutritional supplement industry, a sector characterized by high competition, evolving consumer preferences for health and wellness products, and significant regulatory scrutiny. The industry relies heavily on independent distributors and network marketing models, which can be sensitive to commission structures and sales incentives.

Regulatory Implications

Companies in the direct selling and supplement space face ongoing regulatory oversight from bodies like the FTC and FDA regarding product claims, marketing practices, and business opportunity disclosures. Non-compliance can lead to significant fines, reputational damage, and operational restrictions.

What Investors Should Do

1. Monitor operating cash flow closely.
2. Analyze inventory turnover and sales trends.
3. Evaluate the effectiveness of cost-saving measures.
4. Assess the impact of increased operating lease liabilities.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported a net income of $1.924 million on net sales of $29.161 million, a quarterly improvement but year-to-date net loss of $3.918 million on sales of $81.403 million.
• 2025-09-30: Cash and Cash Equivalents — Stood at $7.141 million, a decrease from $11.396 million at the end of 2024, reflecting negative operating cash flow.
• 2025-09-30: Total Assets — Decreased to $33.920 million from $36.056 million at the end of 2024.
• 2024-12-31: End of Fiscal Year 2024 — Company had $11.396 million in cash and cash equivalents and $36.056 million in total assets.

Glossary

Deferred commissions

Costs incurred by a company to obtain new customer contracts that are capitalized and amortized over the expected customer life. These are assets on the balance sheet. (A decrease in deferred commissions from $1.259 million to $909 thousand suggests a reduction in new business acquisition costs or a change in amortization policy.)

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income. It represents a negative balance in retained earnings. (The company has an accumulated deficit of $2.729 million as of September 30, 2025, indicating that cumulative losses exceed cumulative profits since inception.)

Treasury stock

Stock that a company has repurchased from the open market. It is recorded at cost and reduces total shareholders' equity. (Mannatech holds $19.562 million in treasury stock, representing 841,927 shares, which reduces the total equity available to common shareholders.)

Operating lease right-of-use assets

An asset recognized under ASC 842 for the right to use an underlying asset for the lease term. (These assets have increased significantly from $2.094 million to $3.753 million, indicating an expansion in leased facilities or equipment.)

Year-Over-Year Comparison

Compared to the prior year, Mannatech Inc. has seen a significant decline in net sales, with a decrease of 8.4% year-to-date for the nine months ended September 30, 2025. This revenue contraction has led to a substantial shift from a net income of $0.228 million to a net loss of $3.918 million year-to-date. While operating expenses have been reduced, the company's cash position has also weakened considerably, with cash and cash equivalents dropping from $11.396 million to $7.141 million, driven by negative operating cash flows.

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share MTEX The Nasdaq Stock Mar

Filing Documents

• mtex20250930_10q.htm (10-Q) — 1584KB
• ex_854661.htm (EX-31.1) — 14KB
• ex_854662.htm (EX-31.2) — 13KB
• ex_854663.htm (EX-32.1) — 6KB
• ex_854664.htm (EX-32.2) — 6KB
• 0001437749-25-034431.txt ( ) — 7571KB
• mtex-20250930.xsd (EX-101.SCH) — 66KB
• mtex-20250930_cal.xml (EX-101.CAL) — 62KB
• mtex-20250930_def.xml (EX-101.DEF) — 374KB
• mtex-20250930_lab.xml (EX-101.LAB) — 355KB
• mtex-20250930_pre.xml (EX-101.PRE) — 421KB
• mtex20250930_10q_htm.xml (XML) — 1379KB

– FINANCIAL INFORMATION

Part I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 2 Condensed Consolidated Balance Sheets (unaudited) 2 Condensed Consolidated Statements of Operations (unaudited) 3 Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) 4 Condensed Consolidated Statements of Shareholders' Equity (unaudited) 5 Condensed Consolidated Statements of Cash Flows (unaudited) 6 Notes to Condensed Consolidated Financial Statements (unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Company Overview 23 Results of Operations 24 Liquidity and Capital Resources 30 Significant Accounting Policies and Critical Estimates 32

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 34

Controls and Procedures

Item 4. Controls and Procedures 34

– OTHER INFORMATION

Part II – OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 35

Risk Factors

Item 1A. Risk Factors 35

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 35

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 35

Other Information

Item 5. Other Information 35

Exhibits

Item 6. Exhibits 36

Signatures

Signatures 37 Table of Contents Special Note Regarding Forward-Looking Statements Certain disclosures and analyses in this Form 10-Q, including information incorporated by reference, may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995 that are subject to various risks and uncertainties. Opinions, forecasts, projections, guidance, or other statements other than statements of historical fact are considered forward-looking statements and reflect only current views about future events and financial performance. Some of these forward-looking statements include statements regarding: management's plans and objectives for future operations; existing cash flows being adequate to fund future operational needs; future plans related to budgets, future capital requirements, market share growth, and anticipated capital projects and obligations; the realization of net deferred tax assets; the ability to curtail operating expenditures; global statutory tax rates remaining unchanged; the impact of future market changes due to exposure to foreign currency translations; the possibility of certain policies, procedures, and internal processes minimizing exposure to market risk; the impact of new accounting pronouncements on financial condition, results of operations, or cash flows; the outcome of new or existing litigation matters; the outcome of new or existing regulatory inquiries or investigations; other assumptions described in this report underlying such forward-looking statements. Although we believe that the expectations included in these forward-looking statements are reasonable, these forward-looking statements are subject to certain events, risks, assumptions, and uncertainties, including those discussed below, the "Risk Factors" s

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements MANNATECH, INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS – (UNAUDITED) (in thousands, except share and per share amounts) September 30, 2025 December 31, 2024 ASSETS Cash and cash equivalents $ 7,141 $ 11,396 Restricted cash 550 550 Accounts receivable, net of allowance of $ 783 and $ 935 38 19 Income tax receivable 732 737 Inventories, net 11,128 10,405 Prepaid expenses and other current assets 1,587 1,755 Deferred commissions 909 1,259 Total current assets 22,085 26,121 Property and equipment, net 3,232 2,858 Operating lease right-of-use assets 3,753 2,094 Other assets 2,828 2,644 Deferred tax assets, net 1,783 1,770 Long-term restricted cash 239 569 Total assets $ 33,920 $ 36,056 LIABILITIES AND SHAREHOLDERS' EQUITY Commissions and incentives payable $ 6,407 $ 8,642 Accrued expenses 3,281 3,832 Deferred revenue 2,290 3,027 Accounts payable 4,005 2,070 Current portion of operating lease liabilities 1,745 1,178 Taxes payable 1,487 1,788 Current notes payable — 84 Current portion of finance lease liabilities 288 275 Total current liabilities 19,503 20,896 Long-term notes payable 2,900 2,900 Operating lease liabilities, excluding current portion 2,702 1,576 Other long-term liabilities 1,402 1,390 Finance lease liabilities, excluding current portion 463 680 Total liabilities 26,970 27,442 Commitments and contingencies Shareholders' equity: Preferred stock, $ 0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding — — Common stock, $ 0.0001 par value, 99,000,000 shares authorized, 2,742,857 shares issued and 1,900,930 shares outstanding as of September 30, 2025 and 2,742,857 shares issued and 1,884,814 shares outstanding as of December 31, 2024 — — Additional paid-in capital 33,000 33,027 (Accumulated deficit) retained earnings ( 2,729 ) 1,189 Accumulated other comprehensive loss

View Full Filing

View this 10-Q filing on SEC EDGAR